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Copyright © 2012 JCBN 2012 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Alzheimer’s disease is a devastating neurodegenerative disorder,
the most common among the dementing illnesses. Acetaminophen
has gaining importance in neurodegenerative diseases by attenuat-
ing the dopaminergic neurodegeneration in Caenorhabditis elegans
model, decreasing the chemokines and the cytokines and increas-
ing the anti apoptotic protein such as Bcl-2 in neuronal cell culture.
The low concentration acetaminophen improved the facilitation
to find the hidden platform in Morris Water Maze Test. Also some
data suggest that acetaminophen could contribute in neuro-
degeneration. The present study was aimed to evaluate the effect
of acetaminophen against colchicine induced cognitive impairment
and oxidative stress in wistar rats. The cognitive learning and
memory behaviour was assessed using step through passive
avoidance paradigm and acetylcholine esterase activity. The
parameters of oxidative stress were assessed by measuring the
malondialdehyde, reduced glutathione and catalase levels in the
whole brain homogenates. There was a significant memory
improvement in the rats received acetaminophen treatment and
it has also decreased the acetylcholine esterase enzyme level,
confirming its nootropic activity. Acetaminophen neither increases
nor decreases the reduced glutathione and catalase in the whole
brain homogenates, showing that acetaminophen is devoid of
any adverse effect on brain antioxidant defense system.
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Introduction Alzheimer’s disease (AD) is a devastating neurodegenerative
disorder and its pathological hallmarks are senile plagues and
neurofibrillary tangles.(1) Oxidative stress and free radicals are the
central to the pathogenesis of AD by forming the neurofibrillary
tangles causing irreversible cellular damage and neuronal dys-
function.(2) Impaired cortical cholinergic neurotransmission
contributes to the amyloid-β (Aβ) pathology and increases the
phosphorylation of tau protein.(3) The intracerebroventricular
administration of colchicine in rats produces cognitive impairment
and oxidative stress by disrupting the microtubule assembly and
this method can be effectively used as an animal model for AD.(4–6)
The most logical route toward therapeutic intervention for neuro-
degenerative diseases involves the identification of small molecules
that have the ability to provide neuroprotection. For example,
acetaminophen protects hippocampal neurons and PC12 cultures
from Aβ peptide-induced oxidative stress through reduction of
lipid peroxidation and by lowering cytoplasmic levels of per-
oxides.(7) Quinolinic acid, a neurotoxic metabolite implicated in
the pathogenesis of neurodegenerative disease, is inhibited by
administration of acetaminophen.(8) Acetaminophen also protects
dopamingeric neurons in vitro from oxidative damage evoked by
acute exposure to 6-hydroxydopamine or excessive levels of
dopamine.(9) Acetaminophen has been shown to blunt neuronal
apoptosis via reduction of the inflammatory transcription factor
NF-κB and reduces the inflammatory protein such as chemokines
and cytokines.(7) Acetaminophen also protects brain endothelial
cells against oxidative stress.(10) So our aim is to determine
nootropic activity of acetaminophen by measuring the acetyl
cholinesterase activity in the rat brain homogenates and in vivo
step through passive avoidance paradigm task and also to study its
effect on brain antioxidant status in colchicine induced neuro-
toxicity in rats.
Materials and Methods
Animals. Wistar albino rats obtained from the Animal House
of the KMCH College of Pharmacy, Coimbatore, and weighing
180–200 g. Following surgery, the animals were kept  under
standard conditions of light and dark cycle with food and water ad
libitum and cages with soft bedding. All the experiments were
carried out between 09:00 and 15:00 h. All procedures described
were reviewed and approved by the Institutional Animal Ethical
Committee (IAEC).
Drug treatment. The administration of colchicine was con-
sidered as day 0. The standard drug, donepezil (2 mg/kg/day, p.o.),
acetaminophen (15.1 mg/kg/day, p.o.), ascorbic acid monoglucoside
(AsAG) (250 mg/kg/day, p.o.) were administered from day 1, 1 h
before the experiments, until the end of the study period.
Colchicine-induced cognitive impairment. Surgery was 
performed according to a protocol previously described by Kumar
and Gupta.(4) Colchicine was administered via the intracerebro-
ventricular (i.c.v.) route. Briefly, the right lateral ventricle was
cannulated in rats under ketamine (100 mg/kg, i.p.) and xylazine
(10 mg/kg, i.p.) anaesthesia using stereotaxic coordinates, 0.6 mm
posterior to the bregma, 1.8 mm right lateral and 2.7 mm below
the cortical surface. Colchicine (15 μg/rat), dissolved in 15 μl of
artificial cerebrospinal fluid (aCSF; in nM: NaCl 147, KCl 2.9,
MgCl2 1.6, CaCl2 1.7 and dextrose 2.2), were slowly injected into
the cannulated right lateral ventricle using a 20 μl Hamilton
syringe and the needle was held in place for 2 min for proper dis-
persal of the drug from the tip. The animals were then divided into
four groups of six each for treatment with aCSF, acetaminophen,
AsAG and donepezil. Sham control groups were subjected to the
same surgical procedure and received aCSF.
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Behavioral assessment.
Step-through passive avoidance apparatus. The apparatus used
for passive avoidance training consisted of two compartment box.
An illuminated chamber (30 × 21 × 20 cm3) made of transparent
plastic was connected by a guillotine door to the dark compart-
ment (30 × 21 × 20 cm3) with black opaque walls and ceiling. The
floors of the two compartments were constructed of stainless steel
rods (3 mm in diameter, 10 mm apart) through which foot-shock
could be delivered from a constant current source.
Training procedure. All the experimental groups were first
habituated to the apparatus. We placed a rat in the illuminated
compartment and 10 s later the guillotine door was raised. Upon
entering the dark compartment the door was closed and the rat was
taken from the dark compartment into the home cage. The habitu-
ation trial was repeated after 30 min and followed by the same
interval by the acquisition trial during which the guillotine door
was closed and a 50 Hz, 1 mA constant current shock was applied
for 2 s immediately after the animal had entered the dark compart-
ment. In all experiments the rat was retrained in the apparatus and
received a foot shock each time if it re entered the dark compart-
ment in 120 s and if it happens for three times we excluded it
from the experiment. Training was terminated when the rat
remained in the light compartment for 120 consecutive seconds.
All the groups were trained before day 0 and the transfer latencies
were assessed in day 7, 14 and day 21.
Retention trial. Recall of this inhibitory stimulus was evaluated
on day 7, 14 and 21 post-training by returning the animals into the
light compartment and recording their latency to enter the dark
compartment (four paws in). If the animal had not entered to the
dark compartment within 300 s, it was returned to its cage and a
maximum latency of 300 s was recorded. This latency served as a
measure of retention performance of the step-through avoidance
response (retention latency).
Biochemical tests. Biochemical tests were carried out 24 h
after the last behavioural test on day 21 following colchicine injec-
tions i.e. on day 22.
Tissue preparation. Animals were sacrificed by decapitation
and brains were removed and rinsed with ice-cold isotonic saline.
Brain samples were then homogenized with 10 times (w/v) ice
cold 0.1 M phosphate buffer (pH 7.4). The homogenates were
centrifuged at 10,000 × g for 15 min and aliquots of supernatant
were separated and used for biochemical estimation.
Measurement of catalase. Catalase activity was measured by the
method of Aebi.(11) A total of 0.1 ml of supernatant is added to
cuvette containing 1.9 ml of 50 mM phosphate buffer (pH 7.0).
The reaction started by the addition of 1 ml freshly prepared
30 mM H2O2. The rate of decomposition of H2O2 was measured
spectrophotometrically from the changes in absorbance at 240 nm.
The activity of catalase was expressed as U/mg protein.(4)
Estimation of reduced glutathione. Glutathione was measured
according to the method of Ellman.(12) The equal quantity of
homogenate was mixed with 10% trichloroacetic acid and
centrifuged to separate the proteins. To 0.1 ml of this supernatant,
2 ml of phosphate buffer (pH 8.4), 0.5 ml of 5,5-dithiobis (2-
nitrobenzoic acid) and 0.4 ml of double distilled water were
added. The mixture was vortexed and the absorbance was read at
412 nm within 15 min. The concentration of reduced glutathione
was expressed as μg/g tissue.
Acetyl cholinesterase activity. Acetyl cholinesterase activity is a
marker of extended loss of the cholinergic system in the brain. The
quantitative measurement of acetyl cholinesterase levels in brain
was performed according to the method of Ellman et al.(13) The
assay mixture contained 0.05 ml of supernatant, 3 ml of 0.01 M
sodium phosphate buffer (pH 8), 0.1 ml of acetylthiocholine
iodide and 0.1 ml of DTNB (Ellman reagent). The change in
absorbance was measured immediately at 412 nm using spectro-
photometer. Results were calculated using molar extinction
coefficient of chromophore (1.36 × 104 M−1cm−1) and expressed as
nmoles of acetyl choline hydrolysed/g tissue.
Lipid peroxidation. The quantitative measurement of lipid
peroxidation in brain was performed according to the method of
Wills.(14) The amount of malondialdehyde, a measure of lipid
peroxidation was measured by reaction with thiobarbituric acid
at 532 nm using a Perkin Elmer lambda 20 spectrophotometer.
The values were calculated using molar extinction coefficient of
chromophore (1.56 × 105 M−1cm−1) and expressed as nmoles/g
tissue.
Estimation of total protein. The protein content of the brain
homogenate was measured by biuret method using bovine serum
albumin as standard.
Statistical analysis. The statistical analysis was performed
by oneway ANOVA followed by Tukey’s test. p<0.05 is con-
sidered to be significant.
Results
Passive avoidance paradigm. In the step through passive
avoidance paradigm task on day 7, 14 and 21, significant decrease
in the escape latency were found in the colchicine treated rats
when compared with the rats received aCSF, whereas the rats
treated with acetaminophen showed significant increase when
compared with the cochicine treated rats on all the tested days.
Similarly the rats treated with donepezil and AsAG also found to
have significantly increased escape latency over colchicine group
on day 7, 14 and 21 (Fig. 1A–C).
Estimation of acetylcholine esterase enzyme. Central 
administration of colchicine did not impart any suppression of
brain acetylcholine esterase levels as compared to the aCSF
treated group, but the rats received acetaminophen had a signifi-
cant decrease when compared with the colchicine and aCSF
group. However the donepezil treated rats also had a significant
decrease in acetylcholine esterase levels as compared to the
colchicine treated rats (Fig. 2).
Estimation of reduced glutathione. Central administration
of colchicine caused a significant depletion of brain reduced
glutathione as compared to the aCSF treated rats. The rats in the
acetaminophen treatment group did not produce any significant
change in the reduced glutathione as compared to the colchicine
treated rats. The group receiving the AsAG showed a significant
difference when compared with colchicine treated group (Fig. 3A).
Estimation of catalalse. Central administration of colchicine
did not cause any depletion of brain catalase as compared to the
aCSF treated rats. Similarly the rats treated with acetaminophen
also did not produce any significant change in the catalase level as
compared to the colchicine treated rats. Whereas the group
receiving the AsAG showed a significant difference when com-
pared with colchicine treated group (Fig. 3B).
Estimation of MDA. Treatment with colchicine caused a
significant elevation in the brain MDA level as compared to the
aCSF treated rats. The acetaminophen received rats showed
significant reduction in MDA level as compared to the colchicine
treated rats. Similarly the rats received the AsAG also showed a
significant difference when compared with colchicine treated
group (Fig. 3C).
Discussion
Study of anti-neuroinflammatory effects of drugs has become
the major research in the treatment of AD.(15,16) The chronic
administration of naproxen (20 and 40 mg/kg, p.o.) and valde-
coxib (10 mg/kg, p.o.) significantly restored acetyl cholinesterase
activity compared to colchicine-injected group.(17) An interesting
clinical study suggests that treatment of pain with acetaminophen
in nursing home residents with moderate-to-severe dementia
facilitated engagement with the environment.(18) Effective manage-
ment of pain can play an important part in the treatment of J. Clin. Biochem. Nutr. | May 2012 | vol. 50 | no. 3 | 243
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agitation and could reduce the number of unnecessary prescrip-
tions for psychotropic drugs.(19) Acetaminophen use reduced pain
behaviours associated with musculoskeletal pain in this sample
of persons with dementia.(20) The anti-inflammatory effect of
acetaminophen in AD has been reported by Landolfi et al.(21) All of
these reports indicate the effectiveness of acetaminophen against
behavioural protection in patients with dementia. Apart from the
mechanism of pain reduction, there was an interesting report
suggesting that the low concentration of acetaminophen improved
the facilitation to find the hidden platform in Morris Water Maze
test.(22) In the present study, intracerebroventricular administration
of colchicine impaired the cognition by decreasing the escape
latencies in the passive avoidance paradigm task. The chronic
administration of acetaminophen (15.1 mg/kg, p.o.) had a signifi-
cant difference in the escape latencies in the passive avoidance
paradigm. Also acetaminophen had decreased the enzyme
acetylcholine esterase in the whole brain homogenates showing
that acetaminophen having nootropic activity. Thus the present
study confirms the role of acetaminophen against the cognitive
impairment induced by colchicine.
There are few negative reports regarding the consumption of
glutathione for the metabolism of acetaminophen. Glutathione
consuming effect of acetaminophen could reduce the plasma
glutathione concentration. Subsequently, the plasma-derived
Fig. 1. A–C, Results of step through passive avoidance test on days 7, 14 and 21 respectively. aCSF, rats treated with artificial cerebrospinal fluid;
Col, rats treated with intracerebroventricular colchicine; Col + APAP, Col + AsAG and Col + DPZ, rats treated with intracerebroventricular colchicine
followed by acetaminophen, ascorbic acid monoglucoside and donepezil respectively. Results are expressed as mean retention latency with
standard error. ###p<0.001 vs Col, **p<0.01, ***p<0.001 vs aCSF (Oneway ANOVA followed by Tukey’s test).
Fig. 2. Determination of acetylcholinesterase activity as mentioned by
nmoles of acetylcholine hydrolysed per g brain tissue. aCSF, rats treated
with artificial cerebrospinal fluid; Col, rats treated with intracerebro-
ventricular colchicine; Col + APAP and Col + DPZ, rats treated with
intracerebroventricular colchicine followed by acetaminophen and
donepezil respectively. Results are expressed as mean retention latency
with standard error. *p<0.05, ***p<0.001 vs aCSF (Oneway ANOVA
followed by Tukey’s test).
Fig. 3. Study of antioxidant parameters in the colchicine induced cognition impaired rats. A, estimation of reduced glutathione (mg/g tissue); B,
estimation of catalase activity (Units/mg protein); C, measurement of MDA levels (nmoles/mg brain tissue). aCSF, rats treated with artificial cerebro-
spinal fluid; Col, rats treated with intracerebroventricular colchicine; Col + APAP and Col + AsAG, rats treated with intracerebroventricular colchi-
cine followed by acetaminophen and ascorbic acid monoglucoside respectively. Results are expressed as mean retention latency with standard error.
###p<0.001 vs Col, ***p<0.001 vs aCSF (Oneway ANOVA followed by Tukey’s test).doi: 10.3164/jcbn.11-73
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glutathione supply to the CNS is reduced and the toxic effect
of oxidative stress is amplified. New evidence suggests that
glutathine cannot cross blood brain barrier(23) and thus the peri-
pheral effect of acetaminophen on glutathione may not influence its
level in the brain. In order to study the effect of acetaminophen on
brain glutathione, we have measured its level in the brain homeo-
genate.  The intracerebroventricular administration of colchicine
decreased the GSH concentration in the whole brain homogenates.
The decreased GSH concentration in the CNS would result in the
declined defence against the oxidative stress and promote the
neuron loss. The chronic administration of acetaminophen (15.1
mg/kg, p.o.) did not affect the brain GSH level, which shows
that peripheral GSH is not the major source in the CNS and
acetaminophen is not contributed in neurodegeneration by having
any decreasing effect on GSH in the whole brain homogenates.
In addition we have measured the brain catalase levels to
determine the effect of acetaminophen on brain antioxidant
system. Catalase has a protective role as a hydrogen peroxide
degrading enzyme. Inhibition of catalase activity with amino-
triazole enhances the cytotoxicity of Alzheimer’s beta amyloid
peptide suggests that catalase is involved in the protection of
neuronal and non neuronal cells types.(24) Catalase was slightly
inhibited (30%) in liver after acetaminophen administration in
mice at a single dose of 375 mg/kg.(25) In the present study,
acetaminophen (15.1 mg/kg, p.o.) neither increases nor decreases
catalase in the whole brain homogenates, confirms that acetamin-
ophen not contributed in neurodegeneration by having any
decreasing effect on the enzyme catalase.
To confirm the effect of acetaminophen treatment on anti-
oxidant defense system, we have also measured the brain MDA
levels as a measure of lipid peroxidation. The rats treated with
acetaminophen were protected from lipid peroxidation indicated
by the low MDA levels which is comparable to the anti-lipid
peroxidative effect of AsAG. These results suggest that the treat-
ment with acetaminophen did not affect the brain antioxidant
defense system and also protects it by preventing lipid peroxida-
tion.
In summary, the present study confirms the nootropic activity of
acetaminophen through increasing the escape latency and de-
creasing the acetyl cholinesterase activity in colchicine induced
cognitive impairment in rats. And also suggesting that acetamino-
phen is devoid of any adverse effect on brain antioxidant system
with a potential to prevent lipid peroxidation.
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